Apply to trial NCT04988945

A few quick questions so the study team can decide if you might be a fit.

RecruitingPhase 2Procedure

TACE and SBRT Followed by Double Immunotherapy for Downstaging Hepatocellular Carcinoma

This study is a prospective phase II, single arm mono-institutional study conducted in Queen Mary Hospital (Hong Kong) assessing the efficacy and safety of the sequential administration of trans-arterial chemo-embolization (TACE) and stereotactic body radiotherapy (SBRT) with immune checkpoint inhibitors in unresectable hepatocellular carcinoma (HCC) patients.

How this works

Answer a few questions
About 5 to 10 minutes. Skip-friendly where possible.
We connect you with the study team
When a site picks up your application, we introduce you to their team directly — with you on the thread.
The team reaches out to schedule screening
Usually within a few business days, via the contact you give.

EmailWe save your progress under this email and copy you when we connect you with the study team.

I agree that Hipa.ai may share my application — my name, contact details, and my answers, including health information — with the official study team for this trial so they can review my responses and contact me.

By continuing, you agree to our terms of service.

TACE and SBRT Followed by Double Immunotherapy for Downstaging Hepatocellular Carcinoma

How this works

Answer a few questions

We connect you with the study team

The team reaches out to schedule screening